- Home
- ALTS vs ONCO Comparison
ALTS vs ONCO Comparison
Compare ALTS & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- ONCO
- Stock Information
- Founded
- ALTS 1976
- ONCO 2018
- Country
- ALTS United States
- ONCO United States
- Employees
- ALTS N/A
- ONCO N/A
- Industry
- ALTS
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- ONCO Health Care
- Exchange
- ALTS NYSE
- ONCO Nasdaq
- Market Cap
- ALTS 30.2M
- ONCO 24.1M
- IPO Year
- ALTS N/A
- ONCO 2022
- Fundamental
- Price
- ALTS $2.19
- ONCO $1.09
- Analyst Decision
- ALTS
- ONCO
- Analyst Count
- ALTS 0
- ONCO 0
- Target Price
- ALTS N/A
- ONCO N/A
- AVG Volume (30 Days)
- ALTS 130.5K
- ONCO 79.3K
- Earning Date
- ALTS 12-06-2024
- ONCO 12-03-2024
- Dividend Yield
- ALTS N/A
- ONCO N/A
- EPS Growth
- ALTS N/A
- ONCO N/A
- EPS
- ALTS N/A
- ONCO N/A
- Revenue
- ALTS $7,110,000.00
- ONCO $1,463,746.00
- Revenue This Year
- ALTS N/A
- ONCO N/A
- Revenue Next Year
- ALTS N/A
- ONCO N/A
- P/E Ratio
- ALTS N/A
- ONCO N/A
- Revenue Growth
- ALTS N/A
- ONCO N/A
- 52 Week Low
- ALTS $0.36
- ONCO $1.01
- 52 Week High
- ALTS $5.26
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- ALTS 45.80
- ONCO 20.90
- Support Level
- ALTS $2.09
- ONCO $1.01
- Resistance Level
- ALTS $2.49
- ONCO $1.26
- Average True Range (ATR)
- ALTS 0.25
- ONCO 0.23
- MACD
- ALTS -0.04
- ONCO -0.07
- Stochastic Oscillator
- ALTS 25.33
- ONCO 6.15
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.